Our vision for 6G is an innovation platform connecting an expansive compute and intelligence fabric for the next decade and beyond. It is a new wireless system that builds on the technical foundation and deployment insights from previous generations.
Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainable wood bioenergy, today announced the public release of its Corporate Sustainability Report for the year ending December 31, 2020.
The world’s soils are disappearing, which is why farmers are finding ways to work with beneficial bacteria to help crops and entire ecosystems thrive together.
Global energy consumption for mobile networks is a hot topic. Carbon footprint and costs generated by energy use is one of our industry’s greatest challenges.
NortonLifeLock and NASSCOM Foundation in India partner on the Cyber Security Skills Development Initiative for Women. The program is designed to create greater opportunities for female engineering grads by equipping them with in-demand job skills.
Learn how Johnson & Johnson sites are improving how and when we get the healthcare products and services we need and serving as a beacon to other manufacturers worldwide.
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection and other applications.
Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.
Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome.
Cascale shares updates on its strategic partnerships with industry stakeholders geared toward shifting the industry into one that gives back more than...
Diverse teams build better products — period. At GoDaddy, we make apps and services that our worldwide community of entrepreneurs can relate to. Our...
In states where Key has a presence, there are approximately 1.7 million low- to moderate-income (LMI) households. Many LMI individuals don’t have bank...
